Arcturus Therapeutics (NASDAQ:ARCT) just reported results for the fourth quarter of 2023.
- Arcturus Therapeutics reported earnings per share of -32 cents. This was above the analyst estimate for EPS of -99 cents.
- The company reported revenue of $33.99 million.
- This was 10.22% worse than the analyst estimate for revenue of $37.86 million.